Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

XENEXenon Pharmaceuticals Inc.

Nasdaq · CIK 0001582313
Filer categoryLarge accelerated filer
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts304

Identity from submissions API

NameXenon Pharmaceuticals Inc.
CIK0001582313
TickersXENE
ExchangesNasdaq
Entity typeoperating
CategoryLarge accelerated filer
SIC2834 Pharmaceutical Preparations
EIN980661854
LEI—
Fiscal year end1231
State of incorporationA1 British Columbia, Canada
Phone(604) 484-3300
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
200 - 3650 GILMORE WAY
BURNABY
British Columbia, Canada
A1
Mailing address
200 - 3650 GILMORE WAY
BURNABY
British Columbia, Canada
A1

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

806 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-005106 005-88403 261556368 34 9302
2026-11-09 S-8 S-8 0001193125-26-453723 333-299931 261536575 33 391685 1 1
2026-11-09 10-Q 10-Q 0001193125-26-453701 001-36687 261536490 34 11219292 1 1
2026-11-09 8-K 8-K 2.02,7.01,9.01 0001193125-26-453521 001-36687 261535752 34 478028 1 1
2026-11-06 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001897612-26-000704 005-88403 261530264 34 7664
2026-11-06 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001897612-26-000699 005-88403 261530163 34 7531
2026-11-05 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-002888 005-88403 261526352 34 11728
2026-10-16 4 4 0001193125-26-424428 7076
2026-10-01 4 4 0001193125-26-410001 4654
2026-10-01 4 4 0001193125-26-409999 5354
2026-09-03 4 4 0001193125-26-382412 6907
2026-08-31 4 4 0001193125-26-377309 7879
2026-08-28 144 xsl144X01/primary_doc.xml 0001950047-26-008816 001-36687 261340624 33 4969
2026-08-13 4 4 0001193125-26-349351 5293
2026-08-13 144 xsl144X01/primary_doc.xml 0001193125-26-349336 001-36687 261274052 33 5231
2026-08-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000902219-26-000248 005-88403 261273323 34 15442
2026-08-07 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-002245 005-88403 261252380 34 11714
2026-08-06 10-Q 10-Q 0001193125-26-338244 001-36687 261249722 34 10151852 1 1
2026-08-06 8-K 8-K 2.02,7.01,9.01 0001193125-26-338019 001-36687 261249138 34 464350 1 1
2026-08-06 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-002171 005-88403 261247277 34 11711
2026-06-08 4 4 0001193125-26-262672 5846
2026-06-08 4 4 0001193125-26-262671 4950
2026-06-05 144 xsl144X01/primary_doc.xml 0001950047-26-005712 001-36687 261069668 33 4799
2026-06-05 144 xsl144X01/primary_doc.xml 0001950047-26-005710 001-36687 261069659 33 4827
2026-06-03 4 4 0001193125-26-256126 12346
2026-06-03 4 4 0001193125-26-256125 11511
2026-06-03 4 4 0001193125-26-256124 11466
2026-06-03 4 4 0001193125-26-256122 11470
2026-06-03 4 4 0001193125-26-256121 13332
2026-06-03 4 4 0001193125-26-256120 11450
2026-06-03 4 4 0001193125-26-256118 13366
2026-06-03 S-8 POS S-8 POS 0001193125-26-255544 333-216543 261061078 33 435452
2026-06-03 S-8 POS S-8 POS 0001193125-26-255539 333-279962 261061058 33 435449
2026-06-03 S-8 POS S-8 POS 0001193125-26-255530 333-265377 261061033 33 435452
2026-06-03 S-8 POS S-8 POS 0001193125-26-255521 333-238895 261061003 33 435452
2026-06-03 S-8 POS S-8 POS 0001193125-26-255517 333-237036 261060984 33 435452
2026-06-03 S-8 POS S-8 POS 0001193125-26-255510 333-230103 261060957 33 435452
2026-06-03 S-8 POS S-8 POS 0001193125-26-255504 333-223497 261060930 33 435452
2026-06-03 S-8 POS S-8 POS 0001193125-26-255486 333-210050 261060876 33 435452
2026-06-03 S-8 POS S-8 POS 0001193125-26-255452 333-202765 261060729 33 435452
2026-06-03 S-8 POS S-8 POS 0001193125-26-255442 333-199860 261060698 33 435549
2026-06-03 S-8 S-8 0001193125-26-255419 333-296457 261060622 33 407735 1 1
2026-06-03 8-K 8-K 5.02,5.07,9.01 0001193125-26-255396 001-36687 261060533 34 971182 1 1
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001274173-26-000118 005-88403 26984204 34 12099
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000902664-26-002464 005-88403 26982491 34 10663
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000938206-26-000027 005-88403 26982179 34 7211
2026-05-13 4 4 0001193125-26-222369 6896
2026-05-07 10-Q 10-Q 0001193125-26-212153 001-36687 26954188 34 8889649 1 1
2026-05-07 8-K 8-K 2.02,7.01,9.01 0001193125-26-211843 001-36687 26952996 34 380206 1 1
2026-04-22 ARS ARS 0001193125-26-170361 001-36687 26883733 34 2803695
2026-04-22 DEFA14A DEFA14A 0001193125-26-170335 001-36687 26883690 34 866971 1 1
2026-04-22 DEF 14A DEF 14A 0001193125-26-170320 001-36687 26883659 34 7178844 1 1
2026-04-13 S-8 S-8 0001193125-26-152844 333-295020 26857837 33 404772 1 1
2026-04-13 8-K 8-K 5.02,9.01 0001193125-26-152834 001-36687 26857796 34 742558 1 1
2026-03-13 4 4 0001193125-26-106727 8600
2026-03-13 4 4 0001193125-26-106726 8569
2026-03-13 4 4 0001193125-26-106724 9310
2026-03-13 144 xsl144X01/primary_doc.xml 0001193125-26-106682 001-36687 26754005 33 5154
2026-03-13 144 xsl144X01/primary_doc.xml 0001193125-26-106681 001-36687 26754002 33 5121
2026-03-13 144 xsl144X01/primary_doc.xml 0001193125-26-106680 001-36687 26753999 33 6438
2026-03-13 8-K 8-K 8.01,9.01 0001193125-26-106144 001-36687 26752527 34 191773 1 1
2026-03-12 8-K 8-K 1.01,8.01,9.01 0001193125-26-104199 001-36687 26748002 34 648436 1 1
2026-03-12 424B5 424B5 0001193125-26-102517 333-281451 26744703 33 679498 1 1
2026-03-11 4 4 0001193125-26-102669 10773
2026-03-11 4 4 0001193125-26-102667 10742
2026-03-11 4 4 0001193125-26-102666 43351
2026-03-11 FWP FWP 0001193125-26-100831 333-281451 26741345 34 92624
2026-03-10 144 xsl144X01/primary_doc.xml 0001193125-26-100805 001-36687 26741314 33 4517
2026-03-10 144 xsl144X01/primary_doc.xml 0001193125-26-100799 001-36687 26741304 33 4550
2026-03-10 144 xsl144X01/primary_doc.xml 0001193125-26-100797 001-36687 26741303 33 5835
2026-03-09 424B5 424B5 0001193125-26-098764 333-281451 26735884 33 504715
2026-03-09 144 xsl144X01/primary_doc.xml 0001193125-26-098734 001-36687 26735768 33 5226
2026-03-09 8-K 8-K 7.01,9.01 0001193125-26-097577 001-36687 26733202 34 11513078 1 1
2026-02-27 8-K 8-K 8.01,9.01 0001193125-26-082520 001-36687 26699511 34 1147911 1 1
2026-02-27 424B5 424B5 0001193125-26-082504 333-281451 26699465 33 620577 1 1
2026-02-26 10-K 10-K 0001193125-26-076650 001-36687 26688172 34 16934986 1 1
2026-02-26 8-K 8-K 2.02,7.01,9.01 0001193125-26-076530 001-36687 26687682 34 421803 1 1
2026-02-10 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902219-26-000084 005-88403 26614316 34 17062
2026-01-09 4 4 0001193125-26-009238 7521
2026-01-09 4 4 0001193125-26-009235 7557
2026-01-09 4 4 0001193125-26-009232 7487
2026-01-09 4 4 0001193125-26-009230 7539
2026-01-02 4 4 0001193125-26-001172 11589
2026-01-02 144 xsl144X01/primary_doc.xml 0001193125-26-001168 001-36687 26503434 33 6402
2025-12-09 4 4 0001193125-25-313147 10074
2025-12-08 144 xsl144X01/primary_doc.xml 0001193125-25-311409 001-36687 251556915 33 7292
2025-12-05 144 xsl144X01/primary_doc.xml 0001193125-25-310009 001-36687 251554084 33 5718
2025-12-03 4 4 0001193125-25-307211 5447
2025-12-01 144 xsl144X01/primary_doc.xml 0001193125-25-304226 001-36687 251541266 33 5113
2025-12-01 S-8 S-8 0001193125-25-303888 333-291868 251539781 33 457654 1 1
2025-12-01 8-K 8-K 5.02,9.01 0001193125-25-303862 001-36687 251539648 34 741396 1 1
2025-11-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001274173-25-000274 005-88403 251482368 34 9390
2025-11-03 10-Q 10-Q 0001193125-25-262646 001-36687 251444614 34 9095174 1 1
2025-11-03 8-K 8-K 2.02,7.01,9.01 0001193125-25-262519 001-36687 251444015 34 438794 1 1
2025-10-17 4 4 0001193125-25-242700 7528
2025-10-17 3 3 0001193125-25-242698 15726
2025-10-17 8-K/A 8-K/A 5.02,8.01,9.01 0001193125-25-242583 001-36687 251401248 34 1402381 1 1
2025-10-16 8-K 8-K 5.02 0001193125-25-241546 001-36687 251398377 34 1400841 1 1
2025-10-01 4 4 0001193125-25-227202 9595
2025-10-01 144 xsl144X01/primary_doc.xml 0001193125-25-227196 001-36687 251366095 33 4593
2025-09-19 144 xsl144X01/primary_doc.xml 0001193125-25-209529 001-36687 251328256 33 4289
2025-08-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902219-25-000271 005-88403 251204910 34 15317
2025-08-11 10-Q 10-Q 0000950170-25-106599 001-36687 251202501 34 9904913 1 1
2025-08-11 8-K 8-K 2.02,7.01,9.01 0000950170-25-106529 001-36687 251201939 34 439207 1 1
2025-08-06 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-002142 005-88403 251188515 34 11179
2025-07-17 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-002959 005-88403 251132117 34 10992
2025-07-03 8-K 8-K 5.02 0000950170-25-093996 001-36687 251106399 34 163338 1 1
2025-06-24 4 4 0000950170-25-089721 5182
2025-06-24 3 3 0000950170-25-089718 15382
2025-06-06 4 4 0000950170-25-083329 7245
2025-06-06 4 4 0000950170-25-083328 7464
2025-06-06 4 4 0000950170-25-083325 7372
2025-06-06 4 4 0000950170-25-083323 7423
2025-06-06 4 4 0000950170-25-083321 9003
2025-06-06 4 4 0000950170-25-083318 7405
2025-06-06 4 4 0000950170-25-083317 7480
2025-06-05 8-K 8-K 5.07,9.01 0000950170-25-082494 001-36687 251028036 34 239357 1 1
2025-05-16 4 4 0000950170-25-073746 6548
2025-05-12 10-Q 10-Q 0000950170-25-069342 001-36687 25935543 34 7871013 1 1
2025-05-12 8-K 8-K 2.02,7.01,9.01 0000950170-25-069183 001-36687 25934806 34 382067 1 1
2025-04-24 ARS ARS 0000950170-25-058092 001-36687 25867676 34 1301535
2025-04-24 DEFA14A DEFA14A 0000950170-25-058088 001-36687 25867663 34 909046 1 1
2025-04-24 DEF 14A DEF 14A 0000950170-25-058086 001-36687 25867658 34 6768651 1 1
2025-03-17 8-K 8-K 8.01,9.01 0000950170-25-040381 001-36687 25745145 34 216566 1 1
2025-03-13 4 4 0000950170-25-039025 7447
2025-03-13 4 4 0000950170-25-039021 7427
2025-03-13 4 4 0000950170-25-039020 7428
2025-03-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-000993 005-88403 25717955 34 11507
2025-03-05 8-K 8-K 4.01,9.01 0000950170-25-033653 001-36687 25711529 34 180484 1 1
2025-02-27 S-8 S-8 0000950170-25-029256 333-285382 25681010 33 450910 1 1
2025-02-27 10-K 10-K 0000950170-25-029149 001-36687 25679892 34 16763145 1 1
2025-02-27 8-K 8-K 2.02,5.02,7.01,9.01 0000950170-25-029010 001-36687 25678618 34 431064 1 1
2025-01-27 4 4 0000950170-25-009388 23665
2025-01-27 144 xsl144X01/primary_doc.xml 0000950170-25-009384 001-36687 25560625 33 5716
2025-01-24 144 xsl144X01/primary_doc.xml 0000950170-25-008888 001-36687 25555109 33 5109
2025-01-23 144 xsl144X01/primary_doc.xml 0000950170-25-008446 001-36687 25551243 33 4501
2025-01-17 8-K 8-K 5.02 0000950170-25-006495 001-36687 25537144 34 166922 1 1
2024-12-19 4 4 0000950170-24-138629 16245
2024-12-18 144 xsl144X01/primary_doc.xml 0000950170-24-138009 001-36687 241560449 33 4076
2024-11-22 4 4 0000950170-24-130378 16359
2024-11-22 144 xsl144X01/primary_doc.xml 0000950170-24-130340 001-36687 241491338 33 3967
2024-11-12 10-Q 10-Q 0000950170-24-125547 001-36687 241449081 34 6194262 1 1
2024-11-12 8-K 8-K 2.02,7.01,9.01 0000950170-24-125374 001-36687 241448125 34 363986 1 1
2024-11-12 SC 13G/A filing.txt 0000315066-24-002938 005-88403 241445050 34 8197
2024-08-09 S-3ASR S-3ASR 0000950170-24-094855 333-281451 241193747 33 1198723 1 1
2024-08-08 10-Q 10-Q 0000950170-24-094109 001-36687 241189091 34 6157497 1 1
2024-08-08 8-K 8-K 2.02,7.01,9.01 0000950170-24-093933 001-36687 241188307 34 362075 1 1
2024-07-12 144 xsl144X01/primary_doc.xml 0000950170-24-083357 001-36687 241115724 33 11105
2024-06-12 144 xsl144X01/primary_doc.xml 0000950170-24-072572 001-36687 241039432 33 5827
2024-06-05 4 4 0000950170-24-069468 14521
2024-06-05 4 4 0000950170-24-069467 14750
2024-06-05 4 4 0000950170-24-069466 14652
2024-06-05 4 4 0000950170-24-069465 5183
2024-06-05 4 4 0000950170-24-069464 5157
2024-06-05 4 4 0000950170-24-069463 14690
2024-06-05 4 4 0000950170-24-069462 14763
2024-06-05 144 xsl144X01/primary_doc.xml 0000950170-24-069439 001-36687 241023128 33 6766
2024-06-05 S-8 S-8 0000950170-24-069340 333-279962 241022283 33 230962
2024-06-05 8-K 8-K 5.07,9.01 0000950170-24-069318 001-36687 241022136 34 629718 1 1
2024-05-09 10-Q 10-Q 0000950170-24-057139 001-36687 24931367 34 5684830 1 1
2024-05-09 8-K 8-K 2.02,7.01,9.01 0000950170-24-056940 001-36687 24930621 34 308719 1 1
2024-04-26 ARS ARS 0000950170-24-049201 001-36687 24884262 34 1158931
2024-04-26 DEF 14A DEF 14A 0000950170-24-049198 001-36687 24884236 34 4941151 1 1
2024-04-19 8-K 8-K 5.02 0000950170-24-046023 001-36687 24858048 34 162259 1 1
2024-03-12 4 4 0000950170-24-030250 14743
2024-03-12 4 4 0000950170-24-030245 14696
2024-03-12 4 4 0000950170-24-030239 14743
2024-03-12 4 4 0000950170-24-030236 14717
2024-03-12 4 4 0000950170-24-030233 14777
2024-03-12 4 4 0000950170-24-030228 14720
2024-03-12 4 4 0000950170-24-030226 14749
2024-03-11 4 4 0000950170-24-029542 19301
2024-03-08 144 xsl144X01/primary_doc.xml 0000950170-24-028834 001-36687 24736123 33 4152
2024-03-08 4 4 0000950170-24-028795 26978
2024-03-08 4 4 0000950170-24-028788 19163
2024-03-08 8-K 8-K 8.01,9.01 0000950170-24-028784 001-36687 24735697 34 188374 1 1
2024-03-07 144 xsl144X01/primary_doc.xml 0000950170-24-028232 001-36687 24731916 33 4135
2024-03-07 144 xsl144X01/primary_doc.xml 0000950170-24-028231 001-36687 24731912 33 4176
2024-02-29 10-K 10-K 0000950170-24-023177 001-36687 24704412 34 11140458 1 1
2024-02-29 8-K 8-K 2.02,7.01,9.01 0000950170-24-023080 001-36687 24703702 34 369624 1 1
2024-02-14 SC 13G/A XENON PHARMACEUTICALS, INC. 0000902664-24-001599 005-88403 24632941 34 60224
2024-02-14 SC 13G/A schedule13g.htm 0000938206-24-000006 005-88403 24632356 34 51857
2024-02-09 SC 13G/A filing.txt 0000315066-24-001592 005-88403 24612681 34 8202
2024-02-08 SC 13G SEC SCHEDULE 13G 0000902219-24-000018 005-88403 24607209 34 37599
2024-01-02 4 4 0000950170-24-000304 4816
2023-12-20 4 4 0000950170-23-071929 10565
2023-12-15 4/A 4/A 0000950170-23-070912 5661
2023-12-15 4 4 0000950170-23-070841 26153
2023-12-14 144 xsl144X01/primary_doc.xml 0001959173-23-005475 001-36687 231487083 33 5263
2023-12-13 144 xsl144X01/primary_doc.xml 0000950170-23-070146 001-36687 231485302 33 4161
2023-11-30 424B5 424B5 0000950170-23-067043 333-260010 231456098 33 1101128
2023-11-30 8-K 8-K 1.01,8.01,9.01 0000950170-23-067040 001-36687 231456039 34 940858 1 1
2023-11-29 424B5 424B5 0000950170-23-066819 333-260010 231453144 33 1058340
2023-11-27 8-K 8-K 8.01,9.01 0000950170-23-066032 001-36687 231437301 34 209729 1 1
2023-11-09 8-K 8-K 8.01,9.01 0000950170-23-062022 001-36687 231392351 34 201468 1 1
2023-11-08 10-Q 10-Q 0000950170-23-061200 001-36687 231388561 34 8355350 1 1
2023-11-08 8-K 8-K 2.02,7.01,9.01 0000950170-23-061119 001-36687 231387968 34 436461 1 1
2023-08-24 4 4 0000950170-23-044403 4925
2023-08-24 144 xsl144X01/primary_doc.xml 0000950170-23-044389 001-36687 231202520 33 4229
2023-08-10 4 4 0000950170-23-041534 5170
2023-08-10 3 3 0000950170-23-041531 13483
2023-08-10 4 4 0000950170-23-041528 5203
2023-08-10 3 3 0000950170-23-041524 13230
2023-08-09 10-Q 10-Q 0000950170-23-040681 001-36687 231155815 34 9169123 1 1
2023-08-09 8-K 8-K 2.01,7.01,9.01 0000950170-23-040608 001-36687 231155378 34 478786 1 1
2023-08-08 8-K 8-K 5.02,9.01 0000950170-23-039782 001-36687 231151260 34 214972 1 1
2023-06-02 4 4 0000950170-23-026195 5069
2023-06-02 4 4 0000950170-23-026190 4926
2023-06-02 4 4 0000950170-23-026184 5078
2023-06-02 4 4 0000950170-23-026178 5161
2023-06-02 4 4 0000950170-23-026171 5104
2023-06-02 4 4 0000950170-23-026169 4904
2023-06-02 4 4 0000950170-23-026167 5203
2023-06-02 8-K 8-K 5.07 0000950170-23-026070 001-36687 23988742 34 282766 1 1
2023-06-01 4 4 0000950170-23-025802 35881
2023-06-01 144 xsl144X01/primary_doc.xml 0000950170-23-025799 001-36687 23986196 33 6577
2023-05-31 144 xsl144X01/primary_doc.xml 0000950170-23-025496 001-36687 23982730 33 6543
2023-05-30 144 xsl144X01/primary_doc.xml 0000950170-23-025011 001-36687 23978504 33 4641
2023-05-26 4 4 0000950170-23-024600 25133
2023-05-24 144 xsl144X01/primary_doc.xml 0001193125-23-153154 001-36687 23955515 33 4518
2023-05-09 10-Q 10-Q 0000950170-23-019775 001-36687 23902775 34 7623836 1 1
2023-05-09 8-K 8-K 2.02,7.01,9.01 0000950170-23-019727 001-36687 23902445 34 393970 1 1
2023-04-27 ARS ARS 0000950170-23-015298 001-36687 23857288 34 853207
2023-04-27 DEF 14A DEF 14A 0000950170-23-015260 001-36687 23856819 34 4428683 1 1
2023-03-24 4 FORM 4 SUBMISSION 0001209191-23-021136 4525
2023-03-14 4 FORM 4 SUBMISSION 0001209191-23-018508 5327
2023-03-14 4 FORM 4 SUBMISSION 0001209191-23-018505 5366
2023-03-14 4 FORM 4 SUBMISSION 0001209191-23-018501 5328
2023-03-14 4 FORM 4 SUBMISSION 0001209191-23-018482 5348
2023-03-14 4 FORM 4 SUBMISSION 0001209191-23-018476 5330
2023-03-14 4 FORM 4 SUBMISSION 0001209191-23-018470 5294
2023-03-14 4 FORM 4 SUBMISSION 0001209191-23-018467 5309
2023-03-14 8-K 8-K 5.02,9.01 0000950170-23-007858 001-36687 23730690 34 341761 1 1
2023-03-09 4 FORM 4 SUBMISSION 0001209191-23-017636 18657
2023-03-08 8-K 8-K 8.01,9.01 0000950170-23-006719 001-36687 23716443 34 240026 1 1
2023-03-01 10-K 10-K 0000950170-23-005582 001-36687 23694282 34 12638995 1 1
2023-03-01 8-K 8-K 2.02,7.01,9.01 0000950170-23-005549 001-36687 23693827 34 480079 1 1
2023-02-14 SC 13G/A SCHEDULE 13G/A, #2 0000899140-23-000395 005-88403 23629691 34 50226
2023-02-14 SC 13G/A XENON PHARMACEUTICALS, INC. 0000902664-23-001690 005-88403 23623551 34 59609
2023-02-14 SC 13G/A AMENDMENT NO. 13 TO THE SCHEDULE 13G 0000921895-23-000486 005-88403 23621339 34 276640
2023-02-10 SC 13G/A schedule13g.htm 0000938206-23-000009 005-88403 23609736 34 52288
2023-02-09 SC 13G/A filing.txt 0000315066-23-002147 005-88403 23605179 34 8065
2022-12-13 4 FORM 4 SUBMISSION 0001209191-22-060939 7144
2022-11-28 4 FORM 4 SUBMISSION 0001209191-22-058916 13789
2022-11-09 4 FORM 4 SUBMISSION 0001209191-22-056248 5360
2022-11-09 3 FORM 3 SUBMISSION 0001209191-22-056243 7167
2022-11-08 10-Q 10-Q 0000950170-22-023283 001-36687 221369488 34 9146726 1 1
2022-11-08 8-K 8-K 2.02,9.01 0000950170-22-023202 001-36687 221368908 34 497229 1 1
2022-11-07 8-K 8-K 8.01,9.01 0000950170-22-022588 001-36687 221365417 34 215158 1 1
2022-09-07 4 FORM 4 SUBMISSION 0001209191-22-049015 25376
2022-09-02 4 FORM 4 SUBMISSION 0001209191-22-048508 24001
2022-08-16 4 FORM 4 SUBMISSION 0001209191-22-046017 16436
2022-08-16 4 FORM 4 SUBMISSION 0001209191-22-046015 14933
2022-08-09 10-Q 10-Q 0001564590-22-028780 001-36687 221148957 34 6507179 1 1
2022-08-09 8-K 8-K 2.02,9.01 0001564590-22-028750 001-36687 221148266 34 426728 1 1
2022-06-29 4 FORM 4 SUBMISSION 0001209191-22-039837 5331
2022-06-29 4 FORM 4 SUBMISSION 0001209191-22-039836 5451
2022-06-29 4 FORM 4 SUBMISSION 0001209191-22-039833 5216
2022-06-29 4 FORM 4 SUBMISSION 0001209191-22-039831 5435
2022-06-29 4 FORM 4 SUBMISSION 0001209191-22-039829 5394
2022-06-29 4 FORM 4 SUBMISSION 0001209191-22-039827 5368
2022-06-29 4 FORM 4 SUBMISSION 0001209191-22-039824 5359
2022-06-23 424B5 424B5 0001564590-22-024069 333-260010 221035520 33 1356305
2022-06-23 8-K 8-K 8.01,9.01 0001564590-22-024065 001-36687 221035435 34 854068 1 1
2022-06-22 424B5 424B5 0001564590-22-023893 333-260010 221032046 33 1293830
2022-06-21 8-K 8-K 8.01,9.01 0001564590-22-023664 001-36687 221026009 34 206996 1 1
2022-06-02 S-8 S-8 0001564590-22-022244 333-265377 22991044 33 236072
2022-06-02 8-K 8-K 5.02,5.07,9.01 0001564590-22-022228 001-36687 22990744 34 746597 1 1
2022-05-10 10-Q 10-Q 0001564590-22-019318 001-36687 22910606 34 5221492 1 1
2022-05-10 8-K 8-K 2.02,9.01 0001564590-22-019282 001-36687 22909829 34 348493 1 1
2022-04-28 DEF 14A DEF 14A 0001564590-22-016439 001-36687 22866532 34 2125079
2022-03-22 8-K 8-K 3.02 0001564590-22-011356 001-36687 22759505 34 162780 1 1
2022-03-21 SC 13G/A AMENDMENT NO. 12 TO THE SCHEDULE 13G 0000921895-22-000915 005-88403 22753877 34 277207
2022-03-14 4 FORM 4 SUBMISSION 0001209191-22-018467 5330
2022-03-14 4 FORM 4 SUBMISSION 0001209191-22-018463 5366
2022-03-14 4 FORM 4 SUBMISSION 0001209191-22-018457 5307
2022-03-14 4 FORM 4 SUBMISSION 0001209191-22-018453 5348
2022-03-14 4 FORM 4 SUBMISSION 0001209191-22-018449 5330
2022-03-14 4 FORM 4 SUBMISSION 0001209191-22-018445 5309
2022-03-14 4 FORM 4 SUBMISSION 0001209191-22-018440 5312
2022-03-10 8-K 8-K 2.02,8.01,9.01 0001564590-22-009639 001-36687 22729152 34 224564 1 1
2022-03-08 4/A FORM 4/A SUBMISSION 0001209191-22-017418 5200
2022-03-08 4 FORM 4 SUBMISSION 0001209191-22-017341 42453
2022-03-08 4 FORM 4 SUBMISSION 0001209191-22-017318 21495
2022-03-08 4 FORM 4 SUBMISSION 0001209191-22-017316 25295
2022-03-01 424B5 424B5 0001564590-22-008105 333-260010 22699614 33 1168932
2022-03-01 8-K 8-K 1.01,9.01 0001564590-22-008072 001-36687 22698883 34 299523 1 1
2022-03-01 10-K 10-K 0001564590-22-008060 001-36687 22698562 34 9287955 1 1
2022-03-01 8-K 8-K 2.02,9.01 0001564590-22-008039 001-36687 22698132 34 352085 1 1
2022-02-14 SC 13G/A SCHEDULE 13G (AMENDMENT NO. 1) 0000899140-22-000322 005-88403 22633294 34 54136
2022-02-14 SC 13G/A AMENDMENT NO. 11 TO THE SCHEDULE 13G 0000921895-22-000538 005-88403 22629139 34 282409
2022-02-14 SC 13G NONE 0001567619-22-003820 005-88403 22626042 34 66379
2022-02-11 SC 13G/A AMENDMENT NO. 3 0000947871-22-000220 005-88403 22622583 34 59938
2022-02-11 SC 13G/A XENON PHARMACEUTICALS, INC. 0000902664-22-001513 005-88403 22617299 34 58529
2022-02-10 SC 13G/A XENON PHARMACEUTICALS INC. 0000902664-22-001405 005-88403 22612157 34 101510
2022-02-09 SC 13G/A filing.txt 0000315066-22-001252 005-88403 22604709 34 8325
2022-01-21 4 FORM 4 SUBMISSION 0001209191-22-004460 4495
2022-01-12 8-K 8-K 3.02,8.01,9.01 0001564590-22-001074 001-36687 22525598 34 375984 1 1
2021-12-17 4 FORM 4 SUBMISSION 0001209191-21-070231 7341
2021-12-10 4 FORM 4 SUBMISSION 0001209191-21-069018 8057
2021-12-07 4 FORM 4 SUBMISSION 0001209191-21-068300 4498
2021-12-01 8-K 8-K 1.01,2.03,9.01 0001564590-21-058942 001-36687 211462880 34 1012027 1 1
2021-11-16 4 FORM 4 SUBMISSION 0001209191-21-064931 5001
2021-11-10 10-Q 10-Q 0001564590-21-056248 001-36687 211397397 34 7100421 1 1
2021-11-10 8-K 8-K 2.02,9.01 0001564590-21-056197 001-36687 211396757 34 433232 1 1
2021-10-28 SC 13G SCHEDULE 13G 0000899140-21-000694 005-88403 211359571 34 58015
2021-10-06 424B5 424B5 0001564590-21-050327 333-260010 211310343 33 1315658
2021-10-06 8-K 8-K 8.01,9.01 0001564590-21-050322 001-36687 211310226 34 879860 1 1
2021-10-05 FWP FWP 0000950123-21-012856 333-260010 211307182 34 110234
2021-10-04 424B5 424B5 0001564590-21-050074 333-260010 211304088 33 1228739
2021-10-04 S-3ASR S-3ASR 0001564590-21-050016 333-260010 211302643 33 596414
2021-10-04 8-K 8-K 8.01,9.01 0001564590-21-049880 001-36687 211300983 34 234432 1 1
2021-09-08 8-K 8-K 3.02,8.01,9.01 0001564590-21-047258 001-36687 211240804 34 384716 1 1
2021-08-25 4 FORM 4 SUBMISSION 0001209191-21-053304 5359
2021-08-25 3 FORM 3 SUBMISSION 0001209191-21-053302 7172
2021-08-23 8-K 8-K 8.01,9.01 0001564590-21-045346 001-36687 211195446 34 193935 1 1
2021-08-11 10-Q 10-Q 0001564590-21-043484 001-36687 211164105 34 6488501 1 1
2021-08-11 8-K 8-K 2.02,9.01 0001564590-21-043446 001-36687 211163628 34 434616 1 1
2021-06-04 4 FORM 4 SUBMISSION 0001209191-21-038431 8950
2021-06-03 4 FORM 4 SUBMISSION 0001209191-21-038079 5558
2021-06-03 4 FORM 4 SUBMISSION 0001209191-21-038070 5542
2021-06-03 4 FORM 4 SUBMISSION 0001209191-21-038067 5493
2021-06-03 4 FORM 4 SUBMISSION 0001209191-21-038063 5475
2021-06-03 4 FORM 4 SUBMISSION 0001209191-21-038058 5466
2021-06-03 4 FORM 4 SUBMISSION 0001209191-21-038055 5501
2021-06-03 3 FORM 3 SUBMISSION 0001209191-21-038049 7139
2021-06-03 8-K 8-K 5.07,8.01 0001564590-21-031608 001-36687 21993659 34 259606 1 1
2021-06-03 4 FORM 4 SUBMISSION 0001209191-21-037707 5362
2021-06-03 4 FORM 4 SUBMISSION 0001209191-21-037692 5337
2021-06-03 3 FORM 3 SUBMISSION 0001209191-21-037672 14201
2021-06-01 4 FORM 4 SUBMISSION 0001209191-21-036802 18889
2021-06-01 4 FORM 4 SUBMISSION 0001209191-21-036798 19553
2021-05-26 4 FORM 4 SUBMISSION 0001209191-21-035911 9433
2021-05-20 4 FORM 4 SUBMISSION 0001209191-21-034400 15317
2021-05-20 4 FORM 4 SUBMISSION 0001209191-21-034396 9039
2021-05-11 10-Q 10-Q 0001564590-21-026590 001-36687 21912011 34 5409724 1 1
2021-05-11 8-K 8-K 2.02,9.01 0001564590-21-026563 001-36687 21911546 34 369369 1 1
2021-04-28 DEF 14A DEF 14A 0001564590-21-021327 001-36687 21864155 34 1739009
2021-03-15 4 FORM 4 SUBMISSION 0001209191-21-020484 5327
2021-03-15 4 FORM 4 SUBMISSION 0001209191-21-020481 5366
2021-03-15 4 FORM 4 SUBMISSION 0001209191-21-020478 5298
2021-03-15 4 FORM 4 SUBMISSION 0001209191-21-020476 5348
2021-03-15 4 FORM 4 SUBMISSION 0001209191-21-020473 5312
2021-03-12 8-K 8-K 5.02,8.01,9.01 0001564590-21-012910 001-36687 21738363 34 239814 1 1
2021-03-10 424B5 424B5 0001564590-21-012120 333-238896 21730937 33 1278483
2021-03-10 8-K 8-K 8.01,9.01 0001564590-21-012118 001-36687 21730896 34 869750 1 1
2021-03-09 424B5 424B5 0001564590-21-011804 333-238896 21727016 33 1239384
2021-03-01 10-K 10-K 0001564590-21-009905 001-36687 21698571 34 10241348 1 1
2021-03-01 8-K 8-K 2.02,5.02,9.01 0001564590-21-009839 001-36687 21697673 34 371290 1 1
2021-02-18 4 FORM 4 SUBMISSION 0001209191-21-012039 17316
2021-02-16 SC 13G/A AMENDMENT NO. 10 TO THE SCHEDULE 13G 0000921895-21-000397 005-88403 21631018 34 284363
2021-02-12 SC 13G/A AMENDMENT NO. 2 0000947871-21-000188 005-88403 21629588 34 69628
2021-02-12 SC 13G/A XENON PHARMACEUTICALS, INC. 0000902664-21-001248 005-88403 21622936 34 58415
2021-02-11 SC 13G/A XENON PHARMACEUTICALS INC. 0000902664-21-001138 005-88403 21616788 34 102958
2021-02-08 SC 13G filing.txt 0000315066-21-001352 005-88403 21599871 34 8315
2021-01-14 8-K/A 8-K/A 5.02 0001564590-21-001141 001-36687 21527530 34 169590 1 1
2021-01-14 8-K 8-K 1.01,5.02,8.01,9.01 0001564590-21-001139 001-36687 21527527 34 861452 1 1
2020-12-15 4 FORM 4 SUBMISSION 0001209191-20-063494 7230
2020-11-05 4 FORM 4 SUBMISSION 0001209191-20-057208 5547
2020-11-05 3 FORM 3 SUBMISSION 0001209191-20-057205 7230
2020-11-05 10-Q 10-Q 0001564590-20-051443 001-36687 201291391 34 6570807 1 1
2020-11-05 8-K 8-K 2.02,5.02,9.01 0001564590-20-051310 001-36687 201290537 34 445947 1 1
2020-10-29 4 FORM 4 SUBMISSION 0001209191-20-056229 12563
2020-10-29 4 FORM 4 SUBMISSION 0001209191-20-056222 7946
2020-09-01 CT ORDER filename1.pdf 20200901,20200901 9999999997-20-004559 333-198666 201153440 33 123231
2020-08-24 4 FORM 4 SUBMISSION 0001209191-20-048095 6136
2020-08-17 4 FORM 4 SUBMISSION 0001209191-20-046974 5359
2020-08-17 3 FORM 3 SUBMISSION 0001209191-20-046970 7219
2020-08-17 8-K 8-K 8.01,9.01 0001564590-20-040375 001-36687 201108019 34 194180 1 1
2020-08-06 424B5 424B5 0001564590-20-037893 333-238896 201082781 33 885522
2020-08-06 8-K 8-K 1.01,9.01 0001564590-20-037867 001-36687 201082502 34 578935 1 1
2020-08-06 10-Q XENE-10Q-20200806-Q2 0001564590-20-037862 001-36687 201082470 34 6603547 1 1
2020-08-06 8-K 8-K 2.02,9.01 0001564590-20-037751 001-36687 201081804 34 450055 1 1
2020-06-22 SC 13G/A AMENDMENT NO. 9 TO THE SCHEDULE 13G 0000921895-20-001824 005-88403 20979598 34 284965
2020-06-12 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2020-06-12 16:30:00 9999999995-20-001418 333-238896 20961802 33 1681
2020-06-10 4 FORM 4 SUBMISSION 0001209191-20-035608 7094
2020-06-10 CORRESP filename1.htm 0001564590-20-028884 13876
2020-06-10 UPLOAD filename1.pdf 0000000000-20-005143 40116
2020-06-03 S-3 S-3 0001564590-20-028142 333-238896 20938934 33 567901
2020-06-03 S-8 S-8 0001564590-20-028139 333-238895 20938932 33 246489
2020-06-03 8-K 8-K 5.02,5.07,9.01 0001564590-20-028137 001-36687 20938922 34 577302
2020-06-02 4 FORM 4 SUBMISSION 0001209191-20-033669 9378
2020-06-02 4 FORM 4 SUBMISSION 0001209191-20-033653 5323
2020-06-02 4 FORM 4 SUBMISSION 0001209191-20-033643 5335
2020-06-02 4 FORM 4 SUBMISSION 0001209191-20-033639 5558
2020-06-02 4 FORM 4 SUBMISSION 0001209191-20-033627 5493
2020-06-02 4 FORM 4 SUBMISSION 0001209191-20-033605 5475
2020-06-02 4 FORM 4 SUBMISSION 0001209191-20-033596 5441
2020-06-02 4 FORM 4 SUBMISSION 0001209191-20-033593 5466
2020-06-02 4 FORM 4 SUBMISSION 0001209191-20-033588 10924
2020-06-02 4 FORM 4 SUBMISSION 0001209191-20-033578 7254
2020-05-28 4 FORM 4 SUBMISSION 0001209191-20-032628 9699
2020-05-26 10-Q/A 10-Q/A 0001564590-20-026807 001-36687 20908020 34 2719760 1
2020-05-22 10-Q/A 10-Q/A 0001564590-20-026739 001-36687 20905913 34 228184 1
2020-05-21 10-Q 10-Q 0001564590-20-026574 001-36687 20902478 34 1749517
2020-05-21 8-K 8-K 2.02,9.01 0001564590-20-026545 001-36687 20901887 34 226797
2020-05-06 8-K 8-K 8.01 0001564590-20-021912 001-36687 20852578 34 41063
2020-04-28 DEF 14A DEF 14A 0001564590-20-019198 001-36687 20824948 34 2031500
2020-03-13 4 FORM 4 SUBMISSION 0001209191-20-018969 5305
2020-03-13 4 FORM 4 SUBMISSION 0001209191-20-018963 5359

Latest XBRL company facts

One latest value per concept from companyfacts (304 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 98.28M 2026-11-05 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
dei EntityPublicFloat Entity Public Float USD 2.40B 2025-06-30 2025 FY 10-K 2026-02-26 0001193125-26-076650
ecd AwardExrcPrice AwardExrcPrice USD/shares 41.9 2025-10-15 DEF 14A 2026-04-22 0001193125-26-170320
ecd AwardGrantDateFairValue AwardGrantDateFairValue USD 5.81M 2025-10-15 DEF 14A 2026-04-22 0001193125-26-170320
ecd AwardUndrlygSecuritiesAmt AwardUndrlygSecuritiesAmt shares 225,000 2025-10-15 DEF 14A 2026-04-22 0001193125-26-170320
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 3.56M 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001193125-26-170320
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 3.57M 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001193125-26-170320
ecd PeerGroupTotalShareholderRtnAmt PeerGroupTotalShareholderRtnAmt USD 120 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001193125-26-170320
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 291 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001193125-26-170320
ecd UndrlygSecurityMktPriceChngPct UndrlygSecurityMktPriceChngPct Rate -0.01 2025-10-15 DEF 14A 2026-04-22 0001193125-26-170320
ffd NetFeeAmt NetFeeAmt USD 996.5 2026-11-09 S-8 2026-11-09 0001193125-26-453723
ffd TtlFeeAmt TtlFeeAmt USD 996.5 2026-11-09 S-8 2026-11-09 0001193125-26-453723
ffd TtlOfferingAmt TtlOfferingAmt USD 11.45M 2026-11-09 S-8 2026-11-09 0001193125-26-453723
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-11-09 S-8 2026-11-09 0001193125-26-453723
us-gaap AccountsAndOtherReceivablesNetCurrent Accounts and Other Receivables, Net, Current USD 8.65M 2025-03-31 2025 Q1 10-Q 2025-05-12 0000950170-25-069342
us-gaap AccountsPayableAndAccruedLiabilitiesCurrent Accounts Payable and Accrued Liabilities, Current USD 44.15M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap AccountsPayableTradeCurrent Accounts Payable, Trade, Current USD 1.93M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 1.47M 2024-12-31 2024 FY 10-K 2025-02-27 0000950170-25-029149
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 859,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-125547
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 42.23M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 5.74M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 15.45M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -5.05M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 30.35M 2014-12-31 2014 FY 10-K 2015-03-12 0001564590-15-001612
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 227.29M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap AdjustmentsToAdditionalPaidInCapitalOther Adjustments to Additional Paid in Capital, Other USD 73,000 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014222
us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD 16.59M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 538,000 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-09 0001564590-20-009385
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 50.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005582
us-gaap AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits Dilutive Securities, Effect on Basic Earnings Per Share, Options and Restrictive Stock Units USD -5,000 2019-04-01 2019-06-30 2020 Q2 10-Q 2020-08-06 0001564590-20-037862
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 12.57M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap Assets Assets USD 1.20B 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap AssetsCurrent Assets, Current USD 960.07M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 1.15B 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 1.96M 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061200
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 1.07B 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 1.07B 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 868.24M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Debt Securities, Available-for-sale, Noncurrent USD 202.68M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 82.56M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD -30.68M 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-06 0001564590-19-029418
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 82.56M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -116.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Class of Warrant or Right, Number of Securities Called by Each Warrant or Right shares 1.51M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 1.51M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2015-06-30 2015 Q2 10-Q 2015-08-13 0001564590-15-007290
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 98.28M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 98.28M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap CommonStockValue Common Stock, Value, Issued USD 2.49B 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -328.86M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 3.64M 2020-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008060
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 709,000 2019-12-31 2020 FY 10-K 2021-03-01 0001564590-21-009905
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 14.09M 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-09 0001564590-20-009385
us-gaap ConversionOfStockAmountIssued1 Conversion of Stock, Amount Issued USD 124,000 2014-01-01 2014-12-31 2016 FY 10-K 2017-03-08 0001564590-17-003716
us-gaap ConversionOfStockSharesConverted1 Conversion of Stock, Shares Converted shares 7.73M 2013-01-01 2013-12-31 2014 FY 10-K 2015-03-12 0001564590-15-001612
us-gaap CumulativeEffectOnRetainedEarningsNetOfTax1 Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) USD -175,000 2019-01-01 2019-03-31 2020 Q1 10-Q/A 2020-05-26 0001564590-20-026807
us-gaap CurrentFederalStateAndLocalTaxExpenseBenefit Current Federal, State and Local, Tax Expense (Benefit) USD 4.78M 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0000950170-25-029149
us-gaap CurrentForeignTaxExpenseBenefit Current Foreign Tax Expense (Benefit) USD 4.21M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 4.21M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DebtInstrumentCarryingAmount Long-term Debt, Gross USD 15.50M 2019-12-31 2019 FY 10-K 2020-03-09 0001564590-20-009385
us-gaap DebtSecuritiesAvailableForSaleAmortizedCostCurrent Debt Securities, Available-for-sale, Amortized Cost, Current USD 870.44M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent Debt Securities, Available-for-sale, Amortized Cost, Noncurrent USD 204.54M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap DebtSecuritiesTradingUnrealizedGainLoss Debt Securities, Trading, Unrealized Gain (Loss) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DeferredCompensationShareBasedArrangementsLiabilityCurrent Deferred Compensation Share-based Arrangements, Liability, Current USD 6.30M 2015-03-31 2015 Q1 10-Q/A 2015-08-13 0001564590-15-007284
us-gaap DeferredFederalStateAndLocalTaxExpenseBenefit Deferred Federal, State and Local, Tax Expense (Benefit) USD -8.86M 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0000950170-25-029149
us-gaap DeferredFinanceCostsNoncurrentNet Debt Issuance Costs, Noncurrent, Net USD 0 2014-12-31 2014 FY 10-K 2015-03-12 0001564590-15-001612
us-gaap DeferredForeignIncomeTaxExpenseBenefit Deferred Foreign Income Tax Expense (Benefit) USD -3.20M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DeferredIncomeTaxAssetsNet Deferred Income Tax Assets, Net USD 15.46M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD -2.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 164,000 2015-06-30 2015 Q2 10-Q 2015-08-13 0001564590-15-007290
us-gaap DeferredRevenue Deferred Revenue USD 11.78M 2014-12-31 2014 FY 10-K 2015-03-12 0001564590-15-001612
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 157,000 2015-12-31 2016 FY 10-K 2017-03-08 0001564590-17-003716
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 157,000 2014-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014222
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 983,000 2020-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005582
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 361.37M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 19.65M 2014-12-31 2014 FY 10-K 2015-03-12 0001564590-15-001612
us-gaap DeferredTaxAssetsInvestments Deferred Tax Assets, Investments USD 20.11M 2014-12-31 2014 FY 10-K 2015-03-12 0001564590-15-001612
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 12.86M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DeferredTaxAssetsLiabilitiesNetNoncurrent Deferred Tax Assets, Net, Noncurrent USD 186,000 2020-03-31 2020 Q1 10-Q/A 2020-05-26 0001564590-20-026807
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 14.58M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 251.70M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 1.90M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DeferredTaxAssetsPropertyPlantAndEquipment Deferred Tax Assets, Property, Plant and Equipment USD 13.66M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsOther Deferred Tax Assets, Tax Credit Carryforwards, Other USD 5.35M 2014-12-31 2014 FY 10-K 2015-03-12 0001564590-15-001612
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 46.53M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 10.84M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 346.79M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DeferredTaxLiabilitiesLeasingArrangements Deferred Tax Liabilities, Leasing Arrangements USD 1.71M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match pure 1 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent pure 0.05 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 1.71M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 738,000 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-12 0001564590-15-001612
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -3.38 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.35 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-10 0001564590-22-019318
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -3.38 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure -0.003 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.15 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.128 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.004 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.012 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent pure 0.003 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure -0.013 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations USD 326,000 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-06 0001564590-19-029418
us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 75,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity USD 1.65M 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014222
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 14.60M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 112.31M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ForeignCurrencyExchangeRateTranslation1 Foreign Currency Exchange Rate, Translation pure 0.76 2023-12-31 2023 FY 10-K 2024-02-29 0000950170-24-023177
us-gaap ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax USD 95,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ForeignCurrencyTransactionGainLossUnrealized Foreign Currency Transaction Gain (Loss), Unrealized USD 626,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap GainLossOnContractTermination Gain (Loss) on Contract Termination USD 4.40M 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-09 0001564590-20-009385
us-gaap GainLossOnSalesOfAssetsAndAssetImpairmentCharges Gain (Loss) on Sale of Assets and Asset Impairment Charges USD 11,000 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014222
us-gaap GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005582
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 72.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap IncentiveFromLessor Incentive from Lessor USD 70,000 2016-12-31 2016 FY 10-K 2017-03-08 0001564590-17-003716
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -351.06M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -324.79M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD 6.17M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap IncomeTaxesPaid Income Taxes Paid USD 1.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 8.42M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD -1.31M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap IncomeTaxPaidFederalAfterRefundReceived IncomeTaxPaidFederalAfterRefundReceived USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap IncomeTaxPaidForeignAfterRefundReceived IncomeTaxPaidForeignAfterRefundReceived USD 8.42M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 44.11M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap IncomeTaxReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount USD -1.44M 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-06 0001564590-19-006514
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -51.73M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap IncomeTaxReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount USD 6.48M 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-29 0000950170-24-023177
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 1.32M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 4.16M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 90,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap IncomeTaxReconciliationOtherReconcilingItems Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount USD 148,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-29 0000950170-24-023177
us-gaap IncomeTaxReconciliationTaxCreditsInvestment Effective Income Tax Rate Reconciliation, Tax Credit, Investment, Amount USD 2.87M 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-29 0000950170-24-023177
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 158.63M 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0000950170-25-029149
us-gaap IncreaseDecreaseInAccountsAndOtherReceivables Increase (Decrease) in Accounts and Other Receivables USD 7.18M 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-12 0000950170-25-069342
us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities USD 4.41M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 614,000 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0000950170-25-029149
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD -3.64M 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-29 0000950170-24-023177
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD -157,000 2016-01-01 2016-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004750
us-gaap IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option USD -133,000 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-09 0001564590-17-009917
us-gaap IncreaseDecreaseInInterestPayableNet Increase (Decrease) in Interest Payable, Net USD 77,000 2012-01-01 2012-12-31 2014 FY 10-K 2015-03-12 0001564590-15-001612
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -1.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap IncreaseDecreaseInOtherOperatingLiabilities Increase (Decrease) in Other Operating Liabilities USD 131,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap IncreaseDecreaseInOtherReceivables Increase (Decrease) in Other Receivables USD -200,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -331,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap IncreaseDecreaseInPrepaidExpense Increase (Decrease) in Prepaid Expense USD -230,000 2018-01-01 2018-06-30 2019 Q2 10-Q 2019-08-06 0001564590-19-029418
us-gaap IncrementalCommonSharesAttributableToContingentlyIssuableShares Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares shares 12,277 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014222
us-gaap IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements shares 1,680 2019-04-01 2019-06-30 2020 Q2 10-Q 2020-08-06 0001564590-20-037862
us-gaap InterestExpense Interest Expense USD 484,000 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005582
us-gaap InterestIncomeDepositsWithFinancialInstitutions Interest Income, Deposits with Financial Institutions USD 3.52M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008060
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 71,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011901
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005582
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 30.67M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap LeaseAndRentalExpense Operating Leases, Rent Expense USD 1.19M 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-06 0001564590-19-006514
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 6.62M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 1.82M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 1.14M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 1.18M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 1.13M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 1.10M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 1.05M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 452,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 612,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap Liabilities Liabilities USD 53.49M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 1.20B 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap LiabilitiesCurrent Liabilities, Current USD 45.30M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap LicenseAndServicesRevenue License and Services Revenue (Deprecated 2018-01-31) USD 31,000 2017-01-01 2017-06-30 2018 Q2 10-Q 2018-08-07 0001564590-18-020018
us-gaap LicensesRevenue Licenses Revenue (Deprecated 2018-01-31) USD 12.35M 2015-01-01 2015-09-30 2015 Q3 10-Q 2015-11-10 0001564590-15-010362
us-gaap LongTermDebtCurrent Long-term Debt, Current Maturities USD 4.65M 2019-12-31 2020 FY 10-K 2021-03-01 0001564590-21-009905
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Long-Term Debt, Maturity, Year One USD 4.65M 2019-12-31 2019 FY 10-K 2020-03-09 0001564590-20-009385
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive Long-Term Debt, Maturity, Year Five USD 4.13M 2018-09-30 2018 Q3 10-Q 2018-11-06 0001564590-18-027475
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Long-Term Debt, Maturity, Year Four USD 4.13M 2019-09-30 2019 Q3 10-Q 2019-11-05 0001564590-19-040449
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Long-Term Debt, Maturity, Year Three USD 4.65M 2019-12-31 2019 FY 10-K 2020-03-09 0001564590-20-009385
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Long-Term Debt, Maturity, Year Two USD 6.20M 2019-12-31 2019 FY 10-K 2020-03-09 0001564590-20-009385
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Long-Term Debt, Maturity, Remainder of Fiscal Year USD 700,000 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011901
us-gaap LongTermDebtNoncurrent Long-term Debt, Excluding Current Maturities USD 10.89M 2019-12-31 2020 FY 10-K 2021-03-01 0001564590-21-009905
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 868.24M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap MarketableSecuritiesNoncurrent Marketable Securities, Noncurrent USD 202.68M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss USD 667,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap MarketableSecuritiesUnrealizedGainLoss Marketable Securities, Unrealized Gain (Loss) USD -4.65M 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-09 0001564590-22-028780
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 843.27M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 119,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011901
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -685.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD 4.98M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011901
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -274.62M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -8.22M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011901
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -323.47M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -234.33M 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0000950170-25-029149
us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Net Income (Loss) Available to Common Stockholders, Diluted USD -7.44M 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-08-06 0001564590-20-037862
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 30.76M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OperatingExpenses Operating Expenses USD 355.55M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -355.55M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OperatingLeaseCost Operating Lease, Cost USD 1.19M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 6.01M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 1.15M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 4.86M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OperatingLeasePayments Operating Lease, Payments USD 1.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 5.05M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 993,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 3.58M 2018-12-31 2018 FY 10-K 2019-03-06 0001564590-19-006514
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 1.13M 2018-12-31 2018 FY 10-K 2019-03-06 0001564590-19-006514
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 279,000 2017-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004750
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 256,000 2018-12-31 2018 FY 10-K 2019-03-06 0001564590-19-006514
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 1.07M 2018-12-31 2018 FY 10-K 2019-03-06 0001564590-19-006514
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 1.13M 2018-12-31 2018 FY 10-K 2019-03-06 0001564590-19-006514
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 1.27M 2015-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014222
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.036 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OperatingLossCarryforwards Operating Loss Carryforwards USD 932.23M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 1.24M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -5.39M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax USD -3.50M 2014-01-01 2014-12-31 2016 FY 10-K 2017-03-08 0001564590-17-003716
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -2.40M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OtherGeneralAndAdministrativeExpense Other General and Administrative Expense USD 24.82M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 3.33M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OtherReceivablesNetCurrent Other Receivables, Net, Current USD 1.17M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap OtherResearchAndDevelopmentExpense Other Research and Development Expense USD 12.35M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic Participating Securities, Distributed and Undistributed Earnings (Loss), Basic USD 8.20M 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014222
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 1.53M 2014-01-01 2014-12-31 2016 FY 10-K 2017-03-08 0001564590-17-003716
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 1.17B 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 692,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2022-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005582
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2022-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005582
us-gaap PreferredStockShareSubscriptions Preferred Stock, Shares Subscribed but Unissued shares 0 2014-11-10 2015 Q1 10-Q/A 2015-08-13 0001564590-15-007284
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 7.73M 2021-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005582
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 8.10M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap PrepaidExpenseAndOtherAssetsNoncurrent Prepaid Expense and Other Assets, Noncurrent USD 9.15M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap PrepaidExpenseNoncurrent Prepaid Expense, Noncurrent USD 7.97M 2026-06-30 2026 Q2 10-Q 2026-08-06 0001193125-26-338244
us-gaap PriorPeriodReclassificationAdjustment Prior Period Reclassification Adjustment USD 1.48M 2024-01-01 2024-06-30 2025 Q2 10-Q 2025-08-11 0000950170-25-106599
us-gaap ProceedsFromDebtNetOfIssuanceCosts Proceeds from Debt, Net of Issuance Costs USD 8.45M 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-09 0001564590-20-009385
us-gaap ProceedsFromInterestReceived Proceeds from Interest Received USD 550,000 2015-01-01 2015-09-30 2015 Q3 10-Q 2015-11-10 0001564590-15-010362
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 12.08M 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0000950170-25-029149
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 29.51M 2023-01-01 2023-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-125547
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised USD 35,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-29 0000950170-24-023177
us-gaap ProceedsFromRepaymentsOfDebt Proceeds from (Repayments of) Debt USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005582
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 481.01M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 10,000 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014222
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 5.74M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -323.47M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 7.46M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap RepaymentsOfNotesPayable Repayments of Notes Payable USD 1.70M 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-08 0001564590-16-014222
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 283.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.57B 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 311,000 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-06 0001564590-19-006514
us-gaap RevenueFromContractWithCustomerIncludingAssessedTax Revenue from Contract with Customer, Including Assessed Tax USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap RevenueRecognitionMilestoneMethodRevenueRecognized Revenue Recognition, Milestone Method, Revenue Recognized USD 23.49M 2014-01-01 2014-09-30 2014 Q3 10-Q 2014-12-15 0001171843-14-005910
us-gaap Revenues Revenues USD 311,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004750
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 3.02M 2022-01-01 2022-12-31 2024 FY 10-K 2025-02-27 0000950170-25-029149
us-gaap RoyaltyRevenue Royalty Revenue (Deprecated 2018-01-31) USD 2,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004750
us-gaap SegmentReportingOtherItemAmount SegmentReportingOtherItemAmount USD -1.41M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 50.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period shares 210,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-125547
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period shares 0 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-125547
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.58 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.038 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 103.92M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 6.35M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 32.02 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 28.44M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 170,167 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 39.21 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 2.57M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 24.35 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares shares 4.80M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares shares 515,289 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value USD/shares 25.39 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price USD/shares 22.62 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 137.66M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 11.67M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 36 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 722,000 2014-12-31 2014 FY 10-K 2015-03-12 0001564590-15-001612
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value USD 56.97M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares shares 2.37M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value USD/shares 24.09 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 23.94 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 43.28 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap SharesOutstanding Shares, Outstanding shares 6.47M 2013-12-31 2014 FY 10-K 2015-03-12 0001564590-15-001612
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 1.15B 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 4.86 2014-10-01 2014 FY 10-K 2015-03-12 0001564590-15-001612
us-gaap StockIssued1 Stock Issued USD 21.82M 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-09 0001564590-20-009385
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 1.80M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 102.49M 2014-01-01 2014-12-31 2016 FY 10-K 2017-03-08 0001564590-17-003716
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 112.15M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap StockIssuedDuringPeriodValueShareBasedCompensationGross Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture USD 228,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 47,000 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0000950170-25-029149
us-gaap StockRedeemedOrCalledDuringPeriodValue Stock Redeemed or Called During Period, Value USD -4.47M 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-09 0001564590-20-009385
us-gaap TaxesPayableCurrent Taxes Payable, Current USD 106,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap TradingSecuritiesDebt Debt Securities, Trading USD 13.87M 2023-12-31 2024 FY 10-K 2025-02-27 0000950170-25-029149
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 13.30M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 747,000 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 588,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 2.46M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations USD 5,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate USD 2.45M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 79.94M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076650
us-gaap VariableLeaseCost Variable Lease, Cost USD 652,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 95.57M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 54.85M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-10 0001564590-22-019318
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 95.57M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453701

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →